Free Trial
Your $100 Credit Is Waiting! Get MarketBeat All Access Today
Lock In $149
Claim MarketBeat All Access Sale Promotion

Solid Biosciences (SLDB) Financials

Solid Biosciences logo
$6.44 -0.06 (-0.98%)
As of 12:52 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for Solid Biosciences

Annual Income Statements for Solid Biosciences

This table shows Solid Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -17 -39 -75 -117 -88 -72 -86 -96 -125 -174
Consolidated Net Income / (Loss)		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Net Income / (Loss) Continuing Operations		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Total Pre-Tax Income 		-24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Total Operating Income		 -26 -55 -76 -119 -88 -72 -106 -104 -130 -179
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 14 8.09 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 14 8.09 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 26 55 76 119 88 86 115 104 130 179
Selling, General & Admin Expense		 5.46 15 18 25 22 27 29 28 33 39
Research & Development Expense		 20 40 58 95 65 59 78 77 96 140
Restructuring Charge		 - - 0.00 0.00 1.94 0.00 7.18 -0.06 0.00 0.00
Total Other Income / (Expense), net		 1.80 1.68 0.89 2.10 0.23 0.07 20 8.24 5.03 4.88
Interest Expense		 - - - - - - - 0.44 0.34 -0.20
Interest & Investment Income		 0.37 0.22 0.62 1.58 0.12 0.06 2.62 7.58 9.47 9.90
Other Income / (Expense), net		 1.43 1.46 0.27 0.52 0.12 0.00 18 1.10 -4.10 -5.23
Basic Earnings per Share		 ($10.14) ($2.88) ($2.25) ($2.91) ($25.50) ($10.14) ($10.10) ($4.83) ($3.06) ($1.99)
Weighted Average Basic Shares Outstanding		 1.70M 13.65M 33.26M 40.29M 3.46M 7.12M 8.51M 19.88M 40.82M 87.50M
Diluted Earnings per Share		 ($10.14) ($2.88) ($2.25) ($2.91) ($25.50) ($10.14) ($10.10) ($4.83) ($3.06) ($1.99)
Weighted Average Diluted Shares Outstanding		 1.70M 13.65M 33.26M 40.29M 3.46M 7.12M 8.51M 19.88M 40.82M 87.50M
Weighted Average Basic & Diluted Shares Outstanding		 1.70M 13.65M 33.26M 40.29M 51.94M 106.77M 19.57M 37.76M 77.49M 98.39M

Quarterly Income Statements for Solid Biosciences

This table shows Solid Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -21 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57
Consolidated Net Income / (Loss)		 -21 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57
Net Income / (Loss) Continuing Operations		 -21 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57
Total Pre-Tax Income 		-21 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57
Total Operating Income		 -23 -22 -27 -28 -35 -40 -40 -42 -48 -49 -57
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 23 22 27 28 35 40 40 42 48 49 57
Selling, General & Admin Expense		 6.41 6.81 7.99 8.33 7.86 9.13 9.14 9.28 9.20 11 11
Research & Development Expense		 17 15 19 19 27 31 31 32 39 38 46
Restructuring Charge		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Other Income / (Expense), net		 2.13 1.93 2.56 2.72 2.46 -2.70 0.77 2.21 2.28 -0.38 0.57
Interest Expense		 0.11 0.10 0.10 0.09 0.08 0.08 0.07 0.06 -0.34 0.01 0.00
Interest & Investment Income		 1.96 1.76 2.65 2.57 2.33 1.93 2.30 2.97 2.59 2.05 2.06
Other Income / (Expense), net		 0.28 0.27 0.00 0.24 0.21 -4.55 -1.46 -0.69 -0.64 -2.43 -1.49
Basic Earnings per Share		 ($1.05) ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52)
Weighted Average Basic Shares Outstanding		 20.06M 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M
Diluted Earnings per Share		 ($1.05) ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52)
Weighted Average Diluted Shares Outstanding		 20.06M 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M
Weighted Average Basic & Diluted Shares Outstanding		 20.18M 37.76M 38.38M 38.60M 39.95M 77.49M 77.52M 77.87M 77.91M 98.39M 98.45M

Annual Cash Flow Statements for Solid Biosciences

This table details how cash moves in and out of Solid Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -21 44 35 -10 79 -34 36 -81 6.34 -20
Net Cash From Operating Activities		 -20 -43 -70 -93 -57 -78 -98 -94 -100 -156
Net Cash From Continuing Operating Activities		 -20 -43 -70 -93 -57 -78 -98 -94 -100 -156
Net Income / (Loss) Continuing Operations		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Consolidated Net Income / (Loss)		 -24 -53 -75 -117 -88 -72 -86 -96 -125 -174
Depreciation Expense		 0.06 0.45 1.57 2.82 3.92 2.96 2.41 2.58 2.46 1.64
Amortization Expense		 0.51 0.21 -0.09 -0.28 -0.02 1.12 0.23 -2.41 -3.59 -1.87
Non-Cash Adjustments To Reconcile Net Income		 0.31 4.87 5.96 14 12 13 -11 11 23 25
Changes in Operating Assets and Liabilities, net		 2.79 4.43 -2.83 7.76 16 -23 -3.69 -8.87 2.85 -6.82
Net Cash From Investing Activities		 -4.05 10 -27 25 6.60 -91 59 9.69 -16 -58
Net Cash From Continuing Investing Activities		 -4.05 10 -27 25 6.60 -91 59 9.69 -16 -58
Purchase of Property, Plant & Equipment		 -0.39 -2.28 -7.78 -4.39 -0.90 -1.28 -3.02 -1.52 -0.65 -1.15
Purchase of Investments		 -26 -19 -44 -31 -0.40 -141 -183 -117 -204 -236
Sale of Property, Plant & Equipment		 - - - - 0.00 0.00 0.60 0.00 0.01 0.09
Sale and/or Maturity of Investments		 22 32 25 60 7.90 51 213 129 189 179
Net Cash From Financing Activities		 3.42 77 132 58 129 135 75 3.12 122 194
Net Cash From Continuing Financing Activities		 3.42 77 132 58 129 135 75 3.12 122 194
Repayment of Debt		 - - - - - - - 0.15 -0.14 -0.30
Repurchase of Common Equity		 0.00 -2.42 -2.17 -2.10 -3.79 - - 0.00 -5.11 0.00
Issuance of Common Equity		 0.00 0.00 134 60 132 135 73 2.97 127 195
Other Financing Activities, net		 0.00 0.00 -0.01 0.00 0.00 0.11 2.28 0.00 0.46 0.01
Cash Interest Paid		 - - - - - - - 0.38 0.00 0.00

Quarterly Cash Flow Statements for Solid Biosciences

This table details how cash moves in and out of Solid Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -43 25 44 -22 -31 16 130 -72 -78 -1.40 237
Net Cash From Operating Activities		 -18 -21 -25 -21 -24 -30 -32 -37 -33 -54 -47
Net Cash From Continuing Operating Activities		 -18 -21 -25 -21 -24 -30 -32 -37 -33 -54 -47
Net Income / (Loss) Continuing Operations		 -21 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57
Consolidated Net Income / (Loss)		 -21 -20 -24 -25 -33 -43 -39 -39 -46 -50 -57
Depreciation Expense		 0.59 0.21 0.33 1.24 0.41 0.49 0.41 0.39 0.38 0.47 0.40
Amortization Expense		 -0.98 -1.15 -0.54 -1.04 -1.21 -0.80 -0.31 -0.49 -0.33 -0.75 -0.62
Non-Cash Adjustments To Reconcile Net Income		 2.26 2.96 2.18 2.67 6.98 11 5.54 4.71 5.08 9.76 7.43
Changes in Operating Assets and Liabilities, net		 1.22 -2.51 -2.85 0.74 2.84 2.13 1.79 -2.54 7.17 -13 2.31
Net Cash From Investing Activities		 -25 45 -38 -5.18 -11 39 -27 -33 -45 47 45
Net Cash From Continuing Investing Activities		 -25 45 -38 -5.18 -11 39 -27 -33 -45 47 45
Purchase of Property, Plant & Equipment		 -0.38 -0.09 -0.15 -0.29 -0.02 -0.20 -0.13 -0.38 -0.09 -0.57 -0.17
Purchase of Investments		 -34 -15 -83 -20 -85 -15 -65 -63 -83 -24 -83
Sale and/or Maturity of Investments		 10 60 45 15 75 54 38 31 38 72 128
Net Cash From Financing Activities		 - 0.51 107 5.00 3.26 6.94 190 -1.60 1.18 5.14 239
Net Cash From Continuing Financing Activities		 - 0.51 107 5.00 3.26 6.94 190 -1.60 1.18 5.14 239
Repayment of Debt		 - 0.07 0.00 -0.08 -0.12 0.06 -0.14 0.05 -0.24 0.03 0.00
Repurchase of Common Equity		 - - -4.83 -0.29 - - 0.00 - - - -13
Issuance of Common Equity		 - 0.44 112 5.36 3.10 6.86 190 -1.66 1.42 5.12 252
Other Financing Activities, net		 - - 0.15 0.01 0.28 0.02 0.00 0.01 - - 0.02
Cash Interest Paid		 - 0.38 0.00 0.18 0.08 0.08 0.07 0.06 -0.04 -0.09 0.00

Annual Balance Sheets for Solid Biosciences

This table presents Solid Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2017 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2017 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 76 103 171 232 260 165 189 233
Total Current Assets		 71 86 159 223 220 130 157 205
Cash & Equivalents		 52 76 155 119 155 74 80 60
Restricted Cash		 0.07 - - - - - 0.00 1.22
Short-Term Investments		 17 7.48 0.00 89 58 50 69 128
Prepaid Expenses		 1.50 2.78 4.16 15 5.92 6.09 8.38 16
Plant, Property, & Equipment, net		 2.43 12 8.15 6.46 9.66 6.62 4.75 4.17
Total Noncurrent Assets		 3.11 5.52 4.12 3.31 31 29 27 23
Other Noncurrent Operating Assets		 3.11 5.52 4.12 3.31 31 29 27 23
Total Liabilities & Shareholders' Equity		 76 103 171 232 260 165 189 233
Total Liabilities		 11 23 39 24 49 38 51 53
Total Current Liabilities		 11 18 24 24 23 15 30 33
Accounts Payable		 5.07 7.12 3.27 4.46 3.24 2.03 4.24 3.22
Accrued Expenses		 5.97 9.18 8.64 9.53 17 10 20 19
Other Current Liabilities		 0.23 1.97 2.21 1.53 2.58 2.32 6.17 11
Total Noncurrent Liabilities		 0.00 5.15 15 0.57 26 24 21 19
Other Noncurrent Operating Liabilities		 0.00 4.41 3.72 0.57 24 24 21 19
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -59 80 132 208 212 126 137 180
Total Preferred & Common Equity		 -59 80 132 208 212 126 137 180
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -59 80 132 208 212 126 137 180
Common Stock		 65 396 537 685 774 785 921 1,138
Retained Earnings		 -124 -316 -405 -477 -563 -659 -783 -958
Accumulated Other Comprehensive Income / (Loss)		 -0.01 0.00 0.00 -0.05 -0.07 0.02 0.05 0.05

Quarterly Balance Sheets for Solid Biosciences

This table presents Solid Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 205 185 249 231 212 344 308 274 423
Total Current Assets		 167 148 214 198 179 313 279 245 397
Cash & Equivalents		 92 49 118 96 64 211 139 61 297
Restricted Cash		 - - - - - - - - 0.64
Short-Term Investments		 69 94 88 94 107 96 129 175 84
Prepaid Expenses		 7.28 5.46 8.13 7.34 8.38 6.49 11 8.71 15
Plant, Property, & Equipment, net		 7.39 7.05 6.39 5.44 5.07 4.48 4.32 4.36 3.91
Total Noncurrent Assets		 30 29 28 28 27 26 25 25 22
Other Noncurrent Operating Assets		 30 29 28 28 27 26 25 25 22
Total Liabilities & Shareholders' Equity		 205 185 249 231 212 344 308 274 423
Total Liabilities		 41 40 38 38 45 49 50 56 49
Total Current Liabilities		 16 16 14 15 23 29 30 36 30
Accounts Payable		 2.97 1.90 1.73 2.52 3.46 6.44 4.70 8.43 5.56
Accrued Expenses		 11 11 10 9.92 13 15 17 19 19
Other Current Liabilities		 2.39 2.45 2.28 2.25 6.17 7.76 8.60 8.86 5.54
Total Noncurrent Liabilities		 25 25 24 23 22 21 20 20 18
Other Noncurrent Operating Liabilities		 25 25 23 23 22 21 20 20 18
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 164 144 211 193 167 294 258 218 374
Total Preferred & Common Equity		 164 144 211 193 167 294 258 218 374
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 164 144 211 193 167 294 258 218 374
Common Stock		 781 783 894 901 908 1,117 1,121 1,126 1,389
Retained Earnings		 -617 -638 -683 -708 -741 -823 -862 -908 -1,015
Accumulated Other Comprehensive Income / (Loss)		 0.01 0.00 -0.00 -0.02 0.12 0.00 -0.04 0.05 -0.01

Annual Metrics And Ratios for Solid Biosciences

This table displays calculated financial ratios and metrics derived from Solid Biosciences' official financial filings.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 0.00 35,432,460.00 45,987,571.00 60,449,341.00 110,295,600.00 7,534,892.00 20,177,440.00 - 77,910,239.00
DEI Adjusted Shares Outstanding		 0.00 0.00 2,362,164.00 3,065,838.00 4,029,956.00 7,353,040.00 7,534,892.00 20,177,440.00 - 77,910,239.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 0.00 -31.67 -38.24 -21.91 -9.82 -11.41 -4.76 - -2.24
Growth Metrics		 - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -18 -38 -53 -84 -62 -51 -75 -73 -91 -125
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -57.70% -66.17% -69.69%
Earnings before Interest and Taxes (EBIT)		 -24 -53 -75 -119 -88 -72 -89 -103 -134 -184
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -24 -53 -74 -116 -84 -68 -86 -103 -135 -185
Valuation Ratios		 - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -34 -57 -81 -42 -73 -74 -76 -76 -128
Efficiency Ratios		 - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 -4.24 0.00 -2.74 -22 0.43 -0.35 2.84 -12 -9.06
Increase / (Decrease) in Invested Capital		 0.00 -4.24 4.24 -2.74 -19 23 -0.79 3.19 -15 2.61
Book Value per Share		 $0.00 ($4.34) $0.00 $1.74 $2.19 $1.89 $28.09 $6.27 $3.44 $2.31
Tangible Book Value per Share		 $0.00 ($4.34) $0.00 $1.74 $2.19 $1.89 $28.09 $6.27 $3.44 $2.31
Total Capital		 0.00 65 0.00 81 133 208 213 126 137 180
Total Debt		 0.00 0.00 0.00 0.73 0.53 0.00 1.70 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.73 0.53 0.00 1.70 0.00 0.00 0.00
Net Debt		 0.00 -69 0.00 -83 -154 -208 -212 -124 -149 -189
Capital Expenditures (CapEx)		 0.39 2.28 7.78 4.39 0.90 1.28 2.42 1.52 0.65 1.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -9.77 0.00 -15 -20 -8.77 -17 -8.42 -22 -17
Debt-free Net Working Capital (DFNWC)		 0.00 59 0.00 68 134 199 197 115 127 172
Net Working Capital (NWC)		 0.00 59 0.00 68 134 199 197 115 127 172
Net Nonoperating Expense (NNE)		 5.87 15 22 34 26 22 11 23 34 49
Net Nonoperating Obligations (NNO)		 0.00 -69 0.00 -83 -154 -208 -212 -124 -149 -189
Total Depreciation and Amortization (D&A)		 0.56 0.65 1.48 2.55 3.90 4.08 2.64 0.17 -1.14 -0.24
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($152.10) ($43.20) ($33.75) $0.00 ($25.50) ($10.20) ($10.10) ($4.83) ($3.06) ($1.99)
Adjusted Weighted Average Basic Shares Outstanding		 113.26K 909.97K 2.36M 0.00 5.68M 7.36M 8.51M 19.88M 40.82M 87.50M
Adjusted Diluted Earnings per Share		 ($152.10) ($43.20) ($33.75) $0.00 ($25.50) ($10.20) ($10.10) ($4.83) ($3.06) ($1.99)
Adjusted Weighted Average Diluted Shares Outstanding		 113.26K 909.97K 2.36M 0.00 5.68M 7.36M 8.51M 19.88M 40.82M 87.50M
Adjusted Basic & Diluted Earnings per Share		 ($152.10) ($43.20) ($33.75) $0.00 ($25.50) ($10.20) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 113.26K 909.97K 2.22M 0.00 3.46M 7.12M 19.57M 37.76M 77.49M 98.39M
Normalized Net Operating Profit after Tax (NOPAT)		 -18 -38 -53 -84 -61 -51 -69 -73 -91 -125
Debt Service Ratios		 - - - - - - - - - -
Payout Ratios		 - - - - - - - - - -

Quarterly Metrics And Ratios for Solid Biosciences

This table displays calculated financial ratios and metrics derived from Solid Biosciences' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 20,060,039.00 20,177,440.00 37,756,877.00 38,379,413.00 38,595,237.00 - 77,492,959.00 77,515,377.00 77,869,071.00 77,910,239.00 98,391,314.00
DEI Adjusted Shares Outstanding		 20,060,039.00 20,177,440.00 37,756,877.00 38,379,413.00 38,595,237.00 - 77,492,959.00 77,515,377.00 77,869,071.00 77,910,239.00 98,391,314.00
DEI Earnings Per Adjusted Shares Outstanding		 -1.05 -1.01 -0.64 -0.65 -0.85 - -0.51 -0.51 -0.59 -0.64 -0.58
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Growth		 -12.10% -39.65% 12.35% -5.48% -53.99% -95.19% -53.00% -55.32% -35.99% - -42.51%
EBIT Growth		 -8.00% -31.83% 15.40% -3.65% -53.14% -102.08% -54.56% -53.86% -39.25% - -41.64%
NOPAT Growth		 -9.38% 35.59% 16.13% -3.52% -52.21% -79.19% -49.10% -50.04% -36.60% - -43.08%
Net Income Growth		 -2.79% -34.22% 19.18% -1.80% -55.98% -109.47% -61.63% -57.47% -39.88% - -44.44%
EPS Growth		 61.25% 42.70% 58.44% 51.20% 24.76% -1.96% 7.81% 31.15% 39.24% - 11.86%
Operating Cash Flow Growth		 12.39% 39.61% 10.01% 21.84% -32.47% -42.37% -26.43% -74.28% -41.18% - -48.29%
Free Cash Flow Firm Growth		 24.30% 19.78% -72.49% 18.60% -13.59% 28.58% 62.63% 13.27% -2.55% - -362.01%
Invested Capital Growth		 67.65% 904.82% 434.38% -15.75% -377.25% -510.91% -316.31% -429.61% -344.30% - 42.30%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Q/Q Growth		 10.42% 1.29% -18.05% -1.05% -30.78% -25.12% 7.47% -2.58% -14.50% - -13.26%
EBIT Q/Q Growth		 14.08% 3.68% -22.11% -2.57% -26.94% -27.10% 6.60% -2.10% -14.89% - -13.44%
NOPAT Q/Q Growth		 13.89% 3.67% -20.65% -3.45% -26.61% -13.40% -0.39% -4.10% -15.27% - -16.00%
Net Income Q/Q Growth		 14.82% 3.07% -19.51% -3.16% -30.52% -30.17% 7.78% -0.50% -15.95% - -13.96%
EPS Q/Q Growth		 16.00% 2.86% 37.25% 4.69% -29.51% -31.65% 43.27% 28.81% -14.29% - -4.00%
Operating Cash Flow Q/Q Growth		 34.84% -16.35% -20.98% 14.79% -10.44% -25.04% -7.44% -17.46% 10.53% - 11.81%
Free Cash Flow Firm Q/Q Growth		 27.73% -11.94% -39.96% 28.11% -0.85% 29.61% 26.76% -66.82% -19.25% - -22.02%
Invested Capital Q/Q Growth		 -58.23% 92.35% 102.68% -48.26% -237.46% -185.08% -6.69% 21.16% -85.29% - 20.70%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Interest Burden Percent		 91.87% 92.46% 90.48% 91.01% 93.58% 95.84% 94.62% 93.14% 94.00% - 96.49%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Equity (ROE)		 0.00% -56.79% -45.75% -50.81% -65.79% -94.57% -55.30% -68.25% -86.83% - -57.37%
Cash Return on Invested Capital (CROIC)		 -6,970.58% -2,681.11% -1,334.47% -2,132.41% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Return on Common Equity (ROCE)		 0.00% -56.79% -45.75% -50.81% -65.79% -94.57% -55.30% -68.25% -86.83% - -57.37%
Return on Equity Simple (ROE_SIMPLE)		 -62.92% 0.00% -42.83% 0.00% 0.00% 0.00% -47.43% 0.00% 0.00% - 0.00%
Net Operating Profit after Tax (NOPAT)		 -16 -16 -19 -19 -25 -28 -28 -29 -34 -35 -40
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.37% -2.83% -2.82% -3.21% -5.16% -10.76% -4.39% -4.49% -5.96% - -4.83%
Return On Investment Capital (ROIC_SIMPLE)		 - -12.32% -8.88% -10.07% -14.75% -20.35% -9.52% -11.30% -15.44% -19.21% -10.72%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings before Interest and Taxes (EBIT)		 -23 -22 -27 -28 -35 -44 -42 -42 -49 -52 -59
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -23 -23 -27 -27 -36 -45 -41 -42 -49 -52 -59
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.35 0.98 2.39 1.13 1.61 1.16 0.97 1.46 2.20 - 1.89
Price to Tangible Book Value (P/TBV)		 0.35 0.98 2.39 1.13 1.61 1.16 0.97 1.46 2.20 - 1.89
Price to Revenue (P/Rev)		 26.26 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.09 51.75 9.18 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to Equity		 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Financial Leverage		 -0.99 -0.99 -0.99 -0.98 -1.01 -1.03 -1.01 -1.02 -1.06 - -1.03
Leverage Ratio		 1.28 1.26 1.21 1.22 1.27 1.34 1.17 1.19 1.26 - 1.15
Compound Leverage Factor		 1.18 1.16 1.10 1.11 1.19 1.29 1.11 1.11 1.19 - 1.11
Debt to Total Capital		 0.00% 0.00% 0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.52% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Common Equity to Total Capital		 100.00% 100.00% 99.48% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% - 100.00%
Debt to EBITDA		 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to EBITDA		 0.00 0.00 2.07 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to EBITDA		 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Debt to NOPAT		 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Net Debt to NOPAT		 0.00 0.00 2.96 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Long-Term Debt to NOPAT		 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Altman Z-Score		 -3.62 -3.26 4.71 -0.28 -0.95 -3.92 0.73 1.13 0.84 - 5.94
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.38 8.94 14.94 13.45 7.85 5.20 10.89 9.34 6.74 - 13.10
Quick Ratio		 9.03 8.52 14.37 12.95 7.49 4.92 10.66 8.98 6.50 - 12.57
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -19 -26 -19 -19 -13 -9.82 -16 -20 -37 -45
Operating Cash Flow to CapEx		 -4,672.85% -23,136.67% -16,907.38% -7,505.94% -158,053.33% -14,531.86% -25,277.78% -9,923.61% -39,378.82% - -28,624.24%
Free Cash Flow to Firm to Interest Expense		 -158.26 -184.11 -276.67 -214.71 -232.38 -178.83 -144.46 -273.12 0.00 - 0.00
Operating Cash Flow to Interest Expense		 -168.84 -204.15 -265.18 -243.94 -289.12 -395.27 -468.38 -623.53 0.00 - 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -172.45 -205.03 -266.75 -247.19 -289.30 -397.99 -470.24 -629.82 0.00 - 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Fixed Asset Turnover		 0.29 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Accounts Payable Turnover		 0.55 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Days Payable Outstanding (DPO)		 668.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Cash Conversion Cycle (CCC)		 -668.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 1.48 2.84 5.76 2.98 -4.10 -12 -12 -9.82 -18 -9.06 -7.19
Invested Capital Turnover		 1.63 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00
Increase / (Decrease) in Invested Capital		 0.60 3.19 7.48 -0.56 -5.57 -15 -18 -13 -14 2.61 5.27
Enterprise Value (EV)		 -92 0.25 298 27 98 11 -20 109 244 - 327
Market Capitalization		 51 124 503 218 269 160 287 377 480 - 708
Book Value per Share		 $7.20 $6.27 $5.58 $5.04 $4.33 $3.44 $3.80 $3.33 $2.80 $2.31 $3.80
Tangible Book Value per Share		 $7.20 $6.27 $5.58 $5.04 $4.33 $3.44 $3.80 $3.33 $2.80 $2.31 $3.80
Total Capital		 144 126 212 193 167 137 294 258 218 180 374
Total Debt		 0.00 0.00 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 1.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -143 -124 -205 -190 -171 -149 -307 -268 -236 -189 -381
Capital Expenditures (CapEx)		 0.38 0.09 0.15 0.29 0.02 0.20 0.13 0.38 0.09 0.57 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -10 -8.42 -6.21 -7.34 -14 -22 -22 -19 -28 -17 -15
Debt-free Net Working Capital (DFNWC)		 133 115 200 183 157 127 285 249 209 172 367
Net Working Capital (NWC)		 133 115 200 183 157 127 285 249 209 172 367
Net Nonoperating Expense (NNE)		 4.80 4.75 5.50 5.62 8.10 15 11 10 12 15 17
Net Nonoperating Obligations (NNO)		 -143 -124 -205 -190 -171 -149 -307 -268 -236 -189 -381
Total Depreciation and Amortization (D&A)		 -0.40 -0.94 -0.21 0.19 -0.80 -0.32 0.10 -0.10 0.05 -0.28 -0.22
Debt-free, Cash-free Net Working Capital to Revenue		 -537.87% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt-free Net Working Capital to Revenue		 6,884.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Net Working Capital to Revenue		 6,884.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.05) ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52)
Adjusted Weighted Average Basic Shares Outstanding		 20.06M 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M
Adjusted Diluted Earnings per Share		 ($1.05) ($1.02) ($0.64) ($0.61) ($0.79) ($1.04) ($0.59) ($0.42) ($0.48) ($0.50) ($0.52)
Adjusted Weighted Average Diluted Shares Outstanding		 20.06M 19.88M 38.16M 40.93M 41.44M 40.82M 66.34M 94.14M 94.42M 87.50M 109.81M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($1.02) $0.00 $0.00 $0.00 ($1.04) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 20.18M 37.76M 38.38M 38.60M 39.95M 77.49M 77.52M 77.87M 77.91M 98.39M 98.45M
Normalized Net Operating Profit after Tax (NOPAT)		 -16 -16 -19 -19 -25 -28 -28 -29 -34 -35 -40
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -215.43 -215.64 -282.73 -313.06 -426.48 -592.63 -610.50 -706.43 0.00 - 0.00
NOPAT to Interest Expense		 -152.64 -152.80 -197.93 -221.04 -300.33 -372.36 -412.30 -486.42 0.00 - 0.00
EBIT Less CapEx to Interest Expense		 -219.05 -216.52 -284.29 -316.31 -426.66 -595.35 -612.35 -712.72 0.00 - 0.00
NOPAT Less CapEx to Interest Expense		 -156.25 -153.68 -199.50 -224.29 -300.52 -375.08 -414.15 -492.70 0.00 - 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Augmented Payout Ratio		 0.00% 0.00% -5.35% -5.64% -4.99% -4.10% -0.20% 0.00% 0.00% - -6.72%

Financials Breakdown Chart

Key Financial Trends

Solid Biosciences (SLDB) has reported quarterly results across 2023–2025. Here are the key trends and takeaways for retail investors based on the latest four years of quarterly data.

  • Strong liquidity cushion in mid-2025: cash and short-term investments totaled roughly $230–270 million in 2025 quarters (e.g., about $138.9M cash + $129.2M investments in 2025 Q2).
  • Ongoing equity funding: the company has raised cash in multiple quarters via issuance of common equity, helping to bolster liquidity despite ongoing losses.
  • Investing activity provides occasional liquidity support: net cash from continuing investing activities was positive in some quarters (e.g., about $47 million in 2025 Q4 from investing activities, driven by the sale/maturity of investments).
  • Positive equity on the books despite losses: total equity remains positive across periods, underpinned by common stock and other equity components, which can provide a buffer for financing operations.
  • No quarterly revenue reported in the period: Total Revenue remains at zero in the presented quarters, indicating no product sale or contract revenue yet.
  • Ongoing cash burn from operations: net cash from continuing operating activities is consistently negative across quarters, signaling ongoing cash burn to fund R&D and SG&A.
  • Non-cash adjustments help modestly: depreciation, amortization, and other non-cash adjustments help reconcile net income to cash flow, but they do not offset the cash burn on a quarterly basis.
  • Steep and persistent losses: quarterly net income and EPS are negative across the period (EPS roughly -0.5 to -1.05 per share, depending on the period and share count).
  • Sustained negative operating cash flow with limited near-term recovery: continued negative operating cash flow creates dependence on external funding to sustain activities.
  • Large accumulated deficits in retained earnings: repeated negative retained earnings reflect ongoing erosion of equity from losses, with high R&D spend relative to zero revenue.
05/22/26 12:53 PM ETAI Generated. May Contain Errors.

Solid Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Solid Biosciences' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Solid Biosciences' net income appears to be on an upward trend, with a most recent value of -$174.33 million in 2025, rising from -$23.77 million in 2016. The previous period was -$124.70 million in 2024. See where experts think Solid Biosciences is headed by visiting Solid Biosciences' forecast page.

Solid Biosciences' total operating income in 2025 was -$179.21 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $179.21 million

Over the last 9 years, Solid Biosciences' total revenue changed from $0.00 in 2016 to $0.00 in 2025, a change of 0.0%.

Solid Biosciences' total liabilities were at $52.53 million at the end of 2025, a 2.2% increase from 2024, and a 366.1% increase since 2017.

In the past 7 years, Solid Biosciences' cash and equivalents has ranged from $52.08 million in 2017 to $155.38 million in 2022, and is currently $59.90 million as of their latest financial filing in 2025.

Over the last 9 years, Solid Biosciences' book value per share changed from 0.00 in 2016 to 2.31 in 2025, a change of 231.1%.


Related Companies

Financial statements for NASDAQ:SLDB last updated on 5/14/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
How to Profit from Elon’s AI lab before it goes public
Elon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...
InvestorPlace | Sponsoredtc pixel
Maybe the Greatest Strategy of the Decade
Nate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...
Monument Traders Alliance | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
One filing just changed the SpaceX IPO forever
SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the larges...
Behind the Markets | Sponsoredtc pixel
SpaceX controls two-thirds of all satellites - and it is about to go public
SpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...
NXT Wave Research | Sponsoredtc pixel
To Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy Tech
President Trump has used emergency executive powers to back a new energy technology described as 326 times mor...
Altimetry | Sponsoredtc pixel